Kristin Peck Net Worth

The estimated Net Worth of Kristin C Peck is at least $46.4 million dollars as of 20 February 2024. Ms. Peck owns over 13,000 units of Zoetis Inc stock worth over $17,548,616 and over the last 12 years she sold ZTS stock worth over $25,559,608. In addition, she makes $3,330,160 as Chief Executive Officer et Director at Zoetis Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Peck ZTS stock SEC Form 4 insiders trading

Kristin has made over 31 trades of the Zoetis Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 13,000 units of ZTS stock worth $599,170 on 20 February 2024.

The largest trade she's ever made was exercising 36,813 units of Zoetis Inc stock on 10 February 2024 worth over $6,994,102. On average, Kristin trades about 3,068 units every 19 days since 2012. As of 20 February 2024 she still owns at least 92,366 units of Zoetis Inc stock.

You can see the complete history of Ms. Peck stock trades at the bottom of the page.

Kristin Peck biography

Kristin C. Peck serves as Chief Executive Officer, Director of the Company. Prior to becoming CEO, Ms. Peck was executive vice president and group president, U.S. Operations, Business Development and Strategy at Zoetis from March 2018 to December 2019. Ms. Peck previously served as our Executive Vice President and President, U.S. Operations from May 2015 to February 2018 and Executive Vice President and Group President from October 2012 through April 2015. In these roles, Ms. Peck helped usher Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in areas including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer’s Executive Leadership Team. Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) as well as in private equity and real estate finance at The Prudential Realty Group, The O’Connor Group and J.P. Morgan. Ms. Peck has been a member of the Thomson Reuters’ Board of Directors since September 2016 and is also a member of the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School. As a recipient of the 2019 Feather in Her Cap Award, she has been recognized for her leadership and contributions to the animal health industry, and her work in mentoring women and helping them advance their careers in animal health. Ms. Peck holds a bachelor’s degree from Georgetown University and an MBA from Columbia Business School. Ms. Peck’s knowledge and leadership of our company as its current CEO, her animal health and pharmaceutical industry experience, along with her public company board experience, make her a valuable member of our Board.

What is the salary of Kristin Peck?

As the Chief Executive Officer et Director of Zoetis Inc, the total compensation of Kristin Peck at Zoetis Inc is $3,330,160. There are 1 executives at Zoetis Inc getting paid more, with Glenn David having the highest compensation of $3,672,350.

How old is Kristin Peck?

Kristin Peck is 48, she's been the Chief Executive Officer et Director of Zoetis Inc since 2020. There are 21 older and 1 younger executives at Zoetis Inc. The oldest executive at Zoetis Inc is William Steere, 83, who is the Independent Director.

Insiders trading at Zoetis Inc

Over the last 12 years, insiders at Zoetis Inc have traded over $876,669,659 worth of Zoetis Inc stock and bought 1,602,140 units worth $77,083,975 . The most active insiders traders include Square Capital Management, ..., Frank A Damelio et Michael B Mccallister. On average, Zoetis Inc executives and independent directors trade stock every 14 days with the average trade being worth of $14,414,921. The most recent stock trade was executed by Soria Ester Banque on 31 July 2024, trading 895 units of ZTS stock currently worth $170,041.

What does Zoetis Inc do?

Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.

Complete history of Ms. Peck stock trades at Blackrock, Pfizer et Zoetis Inc

Zoetis Inc executives and stock owners

Zoetis Inc executives and other stock owners filed with the SEC include:

• Glenn David,
  Chief Financial Officer, Executive Vice President
• Kristin Peck,
  Chief Executive Officer, Director
• Catherine Knupp,
  Executive Vice President, President - Research and Development
• Kristin C. Peck,
  CEO & Director
• Wafaa Mamilli,
  Exec. VP and Chief Information & Digital Officer
• Roman Trawicki,
  Exec. VP and Pres of Global Manufacturing & Supply
• Glenn C. David,
  Exec. VP and Group Pres of International Operations, Aquaculture, BioDevices & Pet Insurance
• Michael McCallister,
  Non-Executive Independent Chairman of the Board
• Robert Scully,
  Independent Director
• Gregory Norden,
  Independent Director
• Paul Bisaro,
  Independent Director
• William Steere,
  Independent Director
• Linda Rhodes,
  Independent Director
• Willie Reed,
  Independent Director
• Louise Parent,
  Independent Director
• Sanjay Khosla,
  Independent Director
• Frank D'Amelio,
  Independent Director
• Roman Trawicki,
  Executive Vice President, President - Global Manufacturing and Supply
• Heidi Chen,
  Executive Vice President, General Counsel, Corporate Secretary
• Roxanne Lagano,
  Chief Human Resource Officer, Executive Vice President and Global Operations
• Heidi C. Chen,
  Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics
• Roxanne Lagano,
  Exec. VP and Chief HR Officer & Global Operations
• Wetteny N. Joseph,
  Exec. VP & CFO
• Timothy J. Bettington,
  Exec. VP and Pres of U.S. Operations & Global Customer Experience
• William Price,
  VP & Chief Communications Officer
• Steven Frank,
  VP of Investor Relations
• Gavin Hattersley,
  Director
• Robert Edward Kelly,
  Executive Vice President
• Alejandro Bernal,
  Executive Vice President
• Juan Ramon Alaix,
  Director
• Clinton A. Jr. Lewis,
  Executive Vice President
• Sherry N Pudloski,
  Executive Vice President
• Robert J Polzer,
  Executive Vice President
• Amy W Schulman,
  Director
• Sandra J. Beaty,
  Executive Vice President
• Joyce J. Lee,
  Executive Vice President
• Douglas E. Giordano,
  Director
• William F Doyle,
  
• Inc Pfizer,
  Director
• Square Capital Management, ...,
  
• Stefan Weiskopf,
  Executive Vice President
• Richard A. Passov,
  EVP, Chief Financial Officer
• Paul Herendeen,
  Exec. V.P. and CFO
• Charles H Hill,
  Director
• Geno J Germano,
  Director
• Andrew Fenton,
  Executive Vice President
• James Michael Mc Farland,
  Executive Vice President
• Wafaa Mamilli,
  Executive Vice President
• Timothy J Bettington,
  Executive Vice President
• Antoinette Renee Leatherberry,
  Director
• Astorga Jeannette Ferran,
  Executive Vice President
• Abhay U Nayak,
  Executive Vice President
• Wetteny Joseph,
  Chief Financial Officer
• Rimma Driscoll,
  Executive Vice President
• Vanessa Broadhurst,
  Director
• Jamie Brannan,
  Executive Vice President
• Nicholas Ashton,
  Executive Vice President
• Soria Ester Banque,
  Executive Vice President